Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior...
Utility Global and Kyocera Join Forces to Scale H2Gen® Manufacturing Globally for Economic Industrial Decarbonization
Partners are investing in high-volume production of electrochemical cells to meet global demand from Steel, Refining, Petrochemical and Chemical sectors HOUSTON, Dec. 12, 2025 /PRNewswire/ -- Utility Global ("Utility"), a U.S.-based global economic...
MMTEC, Inc. Announces Receipt of Nasdaq Decision Regarding Minimum Bid Price Deficiency
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- MMTEC, Inc. (NASDAQ: MTC) ("MMTEC", "we", "our" or the "Company"), a China-based technology company that provides access to the U.S. financial markets, today announced that on December 9, 2025, the Company...
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody)...
LG TO SHOWCASE NEXT-GENERATION MOBILITY TECHNOLOGY POWERED BY GENERATIVE AI AT CES 2026
Integrating Advanced AI Models with High-Performance Computing Powered by Snapdragon Cockpit Elite Platform, LG Sets New Standards for the AI-Defined Vehicle Era SEOUL, South Korea, Dec. 11, 2025 /PRNewswire/ -- LG Electronics (LG), a global leader...
Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights
Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential Synergistic and complementary to Lee's Pharm's existing products pipeline, and Acquisition of rights as licensor and manufacturer of...
The Frost & Sullivan Institute Honors Global Organizations Advancing Sustainable Progress with the 2025 Visionary Growth Leadership Best Practices Recognition
SANTA CLARA, Calif., Dec. 9, 2025 /PRNewswire/ -- The Frost & Sullivan Institute is pleased to announce the recipients of the 2025 Visionary Growth Leadership Best Practices Recognition. This honor celebrates organizations that are redefining...
Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025
HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen...
Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase III HARMONi-6 study (AK112-306) were shared in an oral presentation by...
Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...